Scholarlink

Background <p>The long-term benefit of beta-blockers (β-blockers) after myocardial infarction (MI) in patients with preserved left-ventricular ejection fraction (LVEF ≥ 40%) remains uncertain in the modern reperfusion era. Earlier trials showed mortality benefits, but contemporary therapies may have altered their effect.</p> Methods <p>We conducted a meta-analysis of randomized controlled trials&#xa0;(RCTs) comparing β-blockers versus no β-blockers in adults with MI and LVEF ≥ 40%. PubMed, Scopus, Web of Science, and Cochrane CENTRAL were searched through October 2025. Primary outcomes were all-cause mortality, recurrent MI, and heart failure (HF). Individual patient data (IPD) were reconstructed from Kaplan–Meier curves for time-to-event analysis, and pooled risk ratios (RRs) and hazard ratios (HRs) were estimated using random-effects models. Trial sequential analysis (TSA), meta-regression, and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) certainty assessments were performed.</p> Results <p>Five RCTs (<i>n</i> = 23,524&#xa0;patients) met inclusion criteria. β-Blockers did not significantly reduce recurrent acute myocardial infarction (AMI) (HR: 0.89 with 95% confidence interval [CI 0.78, 1.02], <i>P</i> = 0.1), HF (HR: 0.92 with 95% CI [0.71, 1.20], <i>P</i> = 0.54), and all-cause mortality (HR: 0.97 with 95% CI [0.85, 1.10], <i>P</i> = 0.63). Secondary endpoints—including major adverse cardiovascular events (MACE), cardiovascular death, stroke, and revascularization—were neutral (<i>P</i> &gt; 0.05). TSA boundaries were not crossed, and meta-regression identified no significant effect modifiers. Evidence certainty was rated low to moderate.</p> Conclusions <p>Among patients with MI and preserved LVEF, β-blockers did not reduce mortality or ischemic or HF events. Routine long-term use offers no prognostic advantage and should be reserved for specific indications such as reduced LVEF, angina, arrhythmia, or hypertension.</p> Registration <p>International Prospective Register of Systematic Reviews (PROSPERO) identifier no. CRD420251175415.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Beta-Blockers After Myocardial Infarction Without Reduced Ejection Fraction: A Meta-Analysis of Kaplan–Meier Reconstructed Individual Patient Data

  • 期刊论文

  • 发表日期：

    2026年2月19日

查看全文
  • Ameer Awashra,
  • Ahmed Emara,
  • Ahmed Mazen Amin,
  • Ahmed W. Hageen,
  • Mohamed S. Elgendy,
  • Mohamed Saad Rakab,
  • Khadeeja Ali Hamzah,
  • Abdullah Faisal Albukhari,
  • Abubakar Nazir,
  • Abdalhakim Shubietah,
  • Anan Abu Rmilah,
  • Mohammed Ruzieh

摘要

Background

The long-term benefit of beta-blockers (β-blockers) after myocardial infarction (MI) in patients with preserved left-ventricular ejection fraction (LVEF ≥ 40%) remains uncertain in the modern reperfusion era. Earlier trials showed mortality benefits, but contemporary therapies may have altered their effect.

Methods

We conducted a meta-analysis of randomized controlled trials (RCTs) comparing β-blockers versus no β-blockers in adults with MI and LVEF ≥ 40%. PubMed, Scopus, Web of Science, and Cochrane CENTRAL were searched through October 2025. Primary outcomes were all-cause mortality, recurrent MI, and heart failure (HF). Individual patient data (IPD) were reconstructed from Kaplan–Meier curves for time-to-event analysis, and pooled risk ratios (RRs) and hazard ratios (HRs) were estimated using random-effects models. Trial sequential analysis (TSA), meta-regression, and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) certainty assessments were performed.

Results

Five RCTs (n = 23,524 patients) met inclusion criteria. β-Blockers did not significantly reduce recurrent acute myocardial infarction (AMI) (HR: 0.89 with 95% confidence interval [CI 0.78, 1.02], P = 0.1), HF (HR: 0.92 with 95% CI [0.71, 1.20], P = 0.54), and all-cause mortality (HR: 0.97 with 95% CI [0.85, 1.10], P = 0.63). Secondary endpoints—including major adverse cardiovascular events (MACE), cardiovascular death, stroke, and revascularization—were neutral (P > 0.05). TSA boundaries were not crossed, and meta-regression identified no significant effect modifiers. Evidence certainty was rated low to moderate.

Conclusions

Among patients with MI and preserved LVEF, β-blockers did not reduce mortality or ischemic or HF events. Routine long-term use offers no prognostic advantage and should be reserved for specific indications such as reduced LVEF, angina, arrhythmia, or hypertension.

Registration

International Prospective Register of Systematic Reviews (PROSPERO) identifier no. CRD420251175415.